Humacyte Stock Performance
| HUMA Stock | USD 4.49 0.11 2.51% |
The company retains a Market Volatility (i.e., Beta) of 2.03, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Humacyte will likely underperform. At this point, Humacyte has a negative expected return of -0.57%. Please make sure to check out Humacyte's maximum drawdown, daily balance of power, period momentum indicator, as well as the relationship between the skewness and day typical price , to decide if Humacyte performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Humacyte has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's primary indicators remain somewhat strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return 2.51 | Five Day Return (7.23) | Year To Date Return 55.36 | Ten Year Return (53.57) | All Time Return (53.57) |
1 | Disposition of 157704 shares by Niklason Laura E of Humacyte at 5.42 subject to Rule 16b-3 | 09/09/2024 |
2 | Disposition of 288674 shares by Niklason Laura E of Humacyte at 5.23 subject to Rule 16b-3 | 09/10/2024 |
3 | Acquisition by Green Charles Bruce of 1200 shares of Humacyte at 4.09 subject to Rule 16b-3 | 09/13/2024 |
4 | Humacyte to Host Virtual KOL Event to Discuss Case Studies on the Use of Acellular Tissue Engineered Vessel in Vascular Trauma Treatment on September 30, 2024 | 09/26/2024 |
5 | Disposition of 716573 shares by Niklason Laura E of Humacyte at 7.78 subject to Rule 16b-3 | 09/27/2024 |
6 | Humacyte, Inc. Investigation Ongoing Contact Levi Korsinsky About Potential Securities Fraud Allegations - HUMA | 10/28/2024 |
7 | Did Humacyte, Inc. Mislead Investors Shareholder Rights Advocates at Levi Korsinsky Investigate - HUMA | 11/06/2024 |
8 | Shareholder Rights Advocates at Levi Korsinsky Investigate Humacyte, Inc. Regarding Possible Securities Fraud Violations | 11/07/2024 |
9 | HUMA ALERT Levi Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Humacyte, Inc. | 11/08/2024 |
10 | ATTENTION Humacyte, Inc. Investors You May Have Been Affected by Fraud- Contact Levi Korsinsky to Discuss Your Rights | 11/11/2024 |
11 | HUMA CLASS ACTION NOTICE Glancy Prongay Murray LLP Files Securities Fraud Lawsuit Against Humacyte, Inc. | 11/18/2024 |
12 | HUMA INVESTOR ALERT Bronstein, Gewirtz Grossman LLC Announces that Humacyte, Inc. ... | 11/19/2024 |
13 | Disposition of 261369 shares by Dougan Brady W of Humacyte at 4.4 subject to Rule 16b-3 | 11/20/2024 |
14 | Humacyte CEO Laura Niklason sells 6.6m in common stock | 11/21/2024 |
15 | HUMA INVESTOR ALERT Bronstein, Gewirtz Grossman LLC Announces that Humacyte, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsui... | 11/22/2024 |
| Begin Period Cash Flow | 149.8 M | |
| Free Cash Flow | -75.6 M |
Humacyte |
Humacyte Relative Risk vs. Return Landscape
If you would invest 705.00 in Humacyte on August 25, 2024 and sell it today you would lose (256.00) from holding Humacyte or give up 36.31% of portfolio value over 90 days. Humacyte is currently does not generate positive expected returns and assumes 5.0345% risk (volatility on return distribution) over the 90 days horizon. In different words, 44% of stocks are less volatile than Humacyte, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Humacyte Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Humacyte's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Humacyte, and traders can use it to determine the average amount a Humacyte's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1124
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | HUMA |
Estimated Market Risk
| 5.03 actual daily | 44 56% of assets are more volatile |
Expected Return
| -0.57 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.11 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Humacyte is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Humacyte by adding Humacyte to a well-diversified portfolio.
Humacyte Fundamentals Growth
Humacyte Stock prices reflect investors' perceptions of the future prospects and financial health of Humacyte, and Humacyte fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Humacyte Stock performance.
| Return On Equity | -8.51 | ||||
| Return On Asset | -0.53 | ||||
| Current Valuation | 574.42 M | ||||
| Shares Outstanding | 128.67 M | ||||
| Price To Earning | 18.04 X | ||||
| Price To Book | 30.28 X | ||||
| Price To Sales | 153.91 X | ||||
| Gross Profit | 1.56 M | ||||
| EBITDA | (96.46 M) | ||||
| Net Income | (110.78 M) | ||||
| Cash And Equivalents | 189.04 M | ||||
| Cash Per Share | 1.84 X | ||||
| Total Debt | 58.11 M | ||||
| Debt To Equity | 0.36 % | ||||
| Current Ratio | 17.46 X | ||||
| Book Value Per Share | (0.53) X | ||||
| Cash Flow From Operations | (73.31 M) | ||||
| Earnings Per Share | (1.34) X | ||||
| Market Capitalization | 577.72 M | ||||
| Total Asset | 128.22 M | ||||
| Retained Earnings | (537.31 M) | ||||
| Working Capital | 64.83 M | ||||
About Humacyte Performance
By analyzing Humacyte's fundamental ratios, stakeholders can gain valuable insights into Humacyte's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Humacyte has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Humacyte has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (1.58) | (1.50) | |
| Return On Tangible Assets | (0.86) | (0.82) | |
| Return On Capital Employed | (0.91) | (0.96) | |
| Return On Assets | (0.86) | (0.82) | |
| Return On Equity | (8.18) | (7.77) |
Things to note about Humacyte performance evaluation
Checking the ongoing alerts about Humacyte for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Humacyte help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Humacyte generated a negative expected return over the last 90 days | |
| Humacyte has high historical volatility and very poor performance | |
| Humacyte has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (110.78 M) with profit before overhead, payroll, taxes, and interest of 1.56 M. | |
| Humacyte currently holds about 189.04 M in cash with (73.31 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.84. | |
| Roughly 27.0% of the company shares are held by company insiders | |
| Latest headline from businesswire.com: HUMA INVESTOR ALERT Bronstein, Gewirtz Grossman LLC Announces that Humacyte, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit |
- Analyzing Humacyte's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Humacyte's stock is overvalued or undervalued compared to its peers.
- Examining Humacyte's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Humacyte's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Humacyte's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Humacyte's stock. These opinions can provide insight into Humacyte's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Humacyte Stock analysis
When running Humacyte's price analysis, check to measure Humacyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Humacyte is operating at the current time. Most of Humacyte's value examination focuses on studying past and present price action to predict the probability of Humacyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Humacyte's price. Additionally, you may evaluate how the addition of Humacyte to your portfolios can decrease your overall portfolio volatility.
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing |